| Subject: | FDA and Roxane Laboratories Issues Nationwide Voluntary Recall of a Single Manufacturing Lot of Azathioprine Tablets |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 20 Jul 2006 - 12:00 am |
| Roxane Laboratories and the FDA have notified pharmacists and other healthcare professionals of a nationwide recall of a single lot of Azathioprine tablets, 50 mg. The lot number is Lot 558470A, Expiration March 2009.
Azathioprine is used to prevent rejection in kidney transplant patients and to manage severe rheumatoid arthritis.
The recall was initiated due to concerns that bottles from this single lot # 558470A, labeled as Azathioprine may contain Methotrexate, 2.5 mg... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
REFERENCE:
External Links:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|